Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06598046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Name: A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC — clinical trial record (NCT06598046)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusUnknown

PhasePhase 2

SponsorHenan Cancer Hospital

Started2024-06-19

View on ClinicalTrials.gov ↗

Record status

This record was last updated September 19, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06

Trial status changed: Recruiting → Unknown

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.

Trial Details

NCT Number	NCT06598046
Lead Sponsor	Henan Cancer Hospital
Conditions	Metastatic Breast Cancer
Enrollment	48 participants
Start Date	2024-06-19
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2024-09-19